Prospective Evaluation of AI-ECG for SHD Detection

Recruiting Observational Study
Valvular Heart Disease Stenosis and Regurgitation (Diagnosis) Pulmonary Hypertension (Diagnosis) Heart Failure With Reduced Ejection Fraction (HFrEF; Diagnosis) Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 90
Sex
Any
Study type
Observational
Participants needed
590 (estimated)
Sponsor
Imperial College London · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study aims to improve the early detection of undiagnosed heart disease, which causes serious health issues, hospital admissions, and high healthcare costs. Researchers are exploring how artificial intelligence (AI) can analyse routine heart tests, called electrocardiograms (ECGs), to detect heart problems. These tests can be done using both traditional ECG machines and portable, wearable devi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients aged 18-90 years * No prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD * Ability to provide informed consent Exclusion Criteria: * Severe arrhythmia or unstable cardiovascular disease * Prior formal diagnosis of HF (including s…
Contacts

Ahmed YM El-Medany, MBChB, MRCP, MSc, FHEA

+44 02075943614

a.el-medany24@imperial.ac.uk

CONTACT